Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

NACompletedINTERVENTIONAL

Enrollment

155

Participants

Timeline

Start Date

June 4, 2004

Primary Completion Date

May 10, 2016

Study Completion Date

June 10, 2016

Conditions

Central Nervous System LymphomaMalignant GliomaMetastatic Malignant Neoplasm in the Brain

Interventions

PROCEDURE

3 Tesla Magnetic Resonance Imaging

Undergo 3T MRI

PROCEDURE

Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Undergo 3T DCE-MRI

PROCEDURE

Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging

Undergo 3T DSC-MRI

DRUG

Ferumoxytol

Given IV

DRUG

Gadolinium

Given IV

PROCEDURE

MRI-Based Angiogram

Undergo MRA

Trial Locations (1)

OHSU Knight Cancer Institute, Portland

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER

NCT00103038 - Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases | Biotech Hunter | Biotech Hunter